Insulin Market Size, Share | Industry Anaysis Report 2022, 2028

    Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin, Fast Acting Insulin); Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes and Prediabetes) and Geography

    Report Code: TIPRE00004051 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET OVERVIEW



    Insulin controls the body's fat and glucose metabolism. It is a peptide hormone that is secreted by beta cells in the islets of Langerhans in the pancreas and helps in glucose metabolism regulation. It promotes glucose to be absorbed from the blood by skeletal muscle cells and fat tissues. But due to some diseases and disorders body not able to make sufficient amout of insulin and which results in hyperglycemia due to imbalnced metabollism. In such conditions insulin is given externally to maintain normal blood glucose levels.

    MARKET SCOPE



    The "Global Insulin Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the insulin market with detailed market segmentation by drug product and indication. The report provides key statistics on the market status of the leading insulin market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION



    • Based on product the market is segmented as, short acting insulin, intermediate acting insulin, long acting insulin, premixed insulin, fast acting insulin.
    • Based on indication the market is segmented as, type 1 diabetes, type 2 diabetes, gestational diabetes and prediabetes.

    MARKET DYNAMICS


    Drivers:



    • Growing prevalence of diabetes across the globe along with rising geriatric population across the globe.
    • Presence of risk factors such as, obesity, unhealthy lifestyles are also expected to spur the market growth during the forecast period.
    • Technological advancements and high R&D investments by pharmaceutical and biopharmaceutical companies.

    Restraints:



    • However, high cost of production along with presence of stringent regulatory guidelines are expected to restrain market growth during the forecast period.

    REGIONAL FRAMEWORK



    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The insulin market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

    The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the insulin market in these regions.

    IMPACT OF COVID-19 ON INSULIN MARKET
    COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. COVID-19 has brought several changes in lives of people with diabetes mellitus. Due to lockdown scenes the daily routine of diabetes patient disrupted they became more sedan and practicing unhealthy diets. COVID-19 outbreak enforced lockdowns in several areas which affected to hospital visits of diabetic patients thus has ultimately affected the demand of insulin and other diabetes therapeutics. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

    MARKET PLAYERS



    The report covers key developments in the insulin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from insulin market are anticipated to lucrative growth opportunities in the future with the rising demand for insulin in the global market.

    The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the insulin market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    • sanofi-aventis U.S. LLC
    • Novo Nordisk A/S
    • Biocon
    • Lilly
    • Wockhardt
    • Bioton
    • Julphar
    • MannKind Corporation
    • USV Private Limited
    • Ypsomed Holding
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Insulin Market - By Product
    1.3.2 Insulin Market - By Indication
    1.3.3 Insulin Market - By Region
    1.3.3.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. INSULIN MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. INSULIN MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. INSULIN MARKET - GLOBAL MARKET ANALYSIS
    6.1. INSULIN - GLOBAL MARKET OVERVIEW
    6.2. INSULIN - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. INSULIN MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
    7.1. OVERVIEW
    7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
    7.3. SHORT ACTING INSULIN
    7.3.1. Overview
    7.3.2. Short Acting Insulin Market Forecast and Analysis
    7.4. INTERMEDIATE ACTING INSULIN
    7.4.1. Overview
    7.4.2. Intermediate Acting Insulin Market Forecast and Analysis
    7.5. LONG ACTING INSULIN
    7.5.1. Overview
    7.5.2. Long Acting Insulin Market Forecast and Analysis
    7.6. PREMIXED INSULIN
    7.6.1. Overview
    7.6.2. Premixed Insulin Market Forecast and Analysis
    7.7. FAST ACTING INSULIN
    7.7.1. Overview
    7.7.2. Fast Acting Insulin Market Forecast and Analysis
    8. INSULIN MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
    8.1. OVERVIEW
    8.2. INDICATION MARKET FORECASTS AND ANALYSIS
    8.3. TYPE 1 DIABETES
    8.3.1. Overview
    8.3.2. Type 1 Diabetes Market Forecast and Analysis
    8.4. TYPE 2 DIABETES
    8.4.1. Overview
    8.4.2. Type 2 Diabetes Market Forecast and Analysis
    8.5. GESTATIONAL DIABETES AND PREDIABETES
    8.5.1. Overview
    8.5.2. Gestational Diabetes and Prediabetes Market Forecast and Analysis

    9. INSULIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    9.1. NORTH AMERICA
    9.1.1 North America Insulin Market Overview
    9.1.2 North America Insulin Market Forecasts and Analysis
    9.1.3 North America Insulin Market Forecasts and Analysis - By Product
    9.1.4 North America Insulin Market Forecasts and Analysis - By Indication
    9.1.5 North America Insulin Market Forecasts and Analysis - By Countries
    9.1.5.1 United States Insulin Market
    9.1.5.1.1 United States Insulin Market by Product
    9.1.5.1.2 United States Insulin Market by Indication
    9.1.5.2 Canada Insulin Market
    9.1.5.2.1 Canada Insulin Market by Product
    9.1.5.2.2 Canada Insulin Market by Indication
    9.1.5.3 Mexico Insulin Market
    9.1.5.3.1 Mexico Insulin Market by Product
    9.1.5.3.2 Mexico Insulin Market by Indication
    9.2. EUROPE
    9.2.1 Europe Insulin Market Overview
    9.2.2 Europe Insulin Market Forecasts and Analysis
    9.2.3 Europe Insulin Market Forecasts and Analysis - By Product
    9.2.4 Europe Insulin Market Forecasts and Analysis - By Indication
    9.2.5 Europe Insulin Market Forecasts and Analysis - By Countries
    9.2.5.1 Germany Insulin Market
    9.2.5.1.1 Germany Insulin Market by Product
    9.2.5.1.2 Germany Insulin Market by Indication
    9.2.5.2 France Insulin Market
    9.2.5.2.1 France Insulin Market by Product
    9.2.5.2.2 France Insulin Market by Indication
    9.2.5.3 Italy Insulin Market
    9.2.5.3.1 Italy Insulin Market by Product
    9.2.5.3.2 Italy Insulin Market by Indication
    9.2.5.4 Spain Insulin Market
    9.2.5.4.1 Spain Insulin Market by Product
    9.2.5.4.2 Spain Insulin Market by Indication
    9.2.5.5 United Kingdom Insulin Market
    9.2.5.5.1 United Kingdom Insulin Market by Product
    9.2.5.5.2 United Kingdom Insulin Market by Indication
    9.2.5.6 Rest of Europe Insulin Market
    9.2.5.6.1 Rest of Europe Insulin Market by Product
    9.2.5.6.2 Rest of Europe Insulin Market by Indication
    9.3. ASIA-PACIFIC
    9.3.1 Asia-Pacific Insulin Market Overview
    9.3.2 Asia-Pacific Insulin Market Forecasts and Analysis
    9.3.3 Asia-Pacific Insulin Market Forecasts and Analysis - By Product
    9.3.4 Asia-Pacific Insulin Market Forecasts and Analysis - By Indication
    9.3.5 Asia-Pacific Insulin Market Forecasts and Analysis - By Countries
    9.3.5.1 Australia Insulin Market
    9.3.5.1.1 Australia Insulin Market by Product
    9.3.5.1.2 Australia Insulin Market by Indication
    9.3.5.2 China Insulin Market
    9.3.5.2.1 China Insulin Market by Product
    9.3.5.2.2 China Insulin Market by Indication
    9.3.5.3 India Insulin Market
    9.3.5.3.1 India Insulin Market by Product
    9.3.5.3.2 India Insulin Market by Indication
    9.3.5.4 Japan Insulin Market
    9.3.5.4.1 Japan Insulin Market by Product
    9.3.5.4.2 Japan Insulin Market by Indication
    9.3.5.5 South Korea Insulin Market
    9.3.5.5.1 South Korea Insulin Market by Product
    9.3.5.5.2 South Korea Insulin Market by Indication
    9.3.5.6 Rest of Asia-Pacific Insulin Market
    9.3.5.6.1 Rest of Asia-Pacific Insulin Market by Product
    9.3.5.6.2 Rest of Asia-Pacific Insulin Market by Indication
    9.4. MIDDLE EAST AND AFRICA
    9.4.1 Middle East and Africa Insulin Market Overview
    9.4.2 Middle East and Africa Insulin Market Forecasts and Analysis
    9.4.3 Middle East and Africa Insulin Market Forecasts and Analysis - By Product
    9.4.4 Middle East and Africa Insulin Market Forecasts and Analysis - By Indication
    9.4.5 Middle East and Africa Insulin Market Forecasts and Analysis - By Countries
    9.4.5.1 South Africa Insulin Market
    9.4.5.1.1 South Africa Insulin Market by Product
    9.4.5.1.2 South Africa Insulin Market by Indication
    9.4.5.2 Saudi Arabia Insulin Market
    9.4.5.2.1 Saudi Arabia Insulin Market by Product
    9.4.5.2.2 Saudi Arabia Insulin Market by Indication
    9.4.5.3 U.A.E Insulin Market
    9.4.5.3.1 U.A.E Insulin Market by Product
    9.4.5.3.2 U.A.E Insulin Market by Indication
    9.4.5.4 Rest of Middle East and Africa Insulin Market
    9.4.5.4.1 Rest of Middle East and Africa Insulin Market by Product
    9.4.5.4.2 Rest of Middle East and Africa Insulin Market by Indication
    9.5. SOUTH AND CENTRAL AMERICA
    9.5.1 South and Central America Insulin Market Overview
    9.5.2 South and Central America Insulin Market Forecasts and Analysis
    9.5.3 South and Central America Insulin Market Forecasts and Analysis - By Product
    9.5.4 South and Central America Insulin Market Forecasts and Analysis - By Indication
    9.5.5 South and Central America Insulin Market Forecasts and Analysis - By Countries
    9.5.5.1 Brazil Insulin Market
    9.5.5.1.1 Brazil Insulin Market by Product
    9.5.5.1.2 Brazil Insulin Market by Indication
    9.5.5.2 Argentina Insulin Market
    9.5.5.2.1 Argentina Insulin Market by Product
    9.5.5.2.2 Argentina Insulin Market by Indication
    9.5.5.3 Rest of South and Central America Insulin Market
    9.5.5.3.1 Rest of South and Central America Insulin Market by Product
    9.5.5.3.2 Rest of South and Central America Insulin Market by Indication

    10. INDUSTRY LANDSCAPE
    10.1. MERGERS AND ACQUISITIONS
    10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    10.3. NEW PRODUCT LAUNCHES
    10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    11. INSULIN MARKET, KEY COMPANY PROFILES
    11.1. SANOFI-AVENTIS U.S. LLC
    11.1.1. Key Facts
    11.1.2. Business Description
    11.1.3. Products and Services
    11.1.4. Financial Overview
    11.1.5. SWOT Analysis
    11.1.6. Key Developments
    11.2. NOVO NORDISK A/S
    11.2.1. Key Facts
    11.2.2. Business Description
    11.2.3. Products and Services
    11.2.4. Financial Overview
    11.2.5. SWOT Analysis
    11.2.6. Key Developments
    11.3. BIOCON
    11.3.1. Key Facts
    11.3.2. Business Description
    11.3.3. Products and Services
    11.3.4. Financial Overview
    11.3.5. SWOT Analysis
    11.3.6. Key Developments
    11.4. LILLY
    11.4.1. Key Facts
    11.4.2. Business Description
    11.4.3. Products and Services
    11.4.4. Financial Overview
    11.4.5. SWOT Analysis
    11.4.6. Key Developments
    11.5. WOCKHARDT
    11.5.1. Key Facts
    11.5.2. Business Description
    11.5.3. Products and Services
    11.5.4. Financial Overview
    11.5.5. SWOT Analysis
    11.5.6. Key Developments
    11.6. BIOTON
    11.6.1. Key Facts
    11.6.2. Business Description
    11.6.3. Products and Services
    11.6.4. Financial Overview
    11.6.5. SWOT Analysis
    11.6.6. Key Developments
    11.7. JULPHAR
    11.7.1. Key Facts
    11.7.2. Business Description
    11.7.3. Products and Services
    11.7.4. Financial Overview
    11.7.5. SWOT Analysis
    11.7.6. Key Developments
    11.8. MANNKIND CORPORATION
    11.8.1. Key Facts
    11.8.2. Business Description
    11.8.3. Products and Services
    11.8.4. Financial Overview
    11.8.5. SWOT Analysis
    11.8.6. Key Developments
    11.9. USV PRIVATE LIMITED
    11.9.1. Key Facts
    11.9.2. Business Description
    11.9.3. Products and Services
    11.9.4. Financial Overview
    11.9.5. SWOT Analysis
    11.9.6. Key Developments
    11.10. YPSOMED HOLDING
    11.10.1. Key Facts
    11.10.2. Business Description
    11.10.3. Products and Services
    11.10.4. Financial Overview
    11.10.5. SWOT Analysis
    11.10.6. Key Developments

    12. APPENDIX
    12.1. ABOUT THE INSIGHT PARTNERS
    12.2. GLOSSARY OF TERMS
    "
    The List of Companies

    1. sanofi-aventis U.S. LLC
    2. Novo Nordisk A/S
    3. Biocon
    4. Lilly
    5. Wockhardt
    6. Bioton
    7. Julphar
    8. MannKind Corporation
    9. USV Private Limited
    10. Ypsomed Holding
    TIPRE00004051
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount